Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 9/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 6/20 | 0.35 |
| ▸ | CNR1 | P21554 | 3/20 | 0.34 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929029 | 0.91 | PDE4B (0.38) | PDE4BPDE4DPDE4ATYK2CNR1 | |
| SCHEMBL4191375 | 0.91 | PDE4B (0.38) | PDE4BPDE4DPDE4ATYK2CNR1 | |
| SCHEMBL5551331 | 0.90 | CNR2 (0.39) | TYK2CNR1CNR2ALDH1A1LMNA | |
| SCHEMBL4188864 | 0.80 | CNR2 (0.39) | PDE4BPDE4DTYK2CNR1CNR2 | |
| SCHEMBL13929031 | 0.80 | CNR2 (0.39) | PDE4BPDE4DTYK2CNR1CNR2 | |
| SCHEMBL5547933 | 0.80 | PDE4B (0.55) | PDE4BPDE4DPDE4ACNR1CNR2 | |
| SCHEMBL5551247 | 0.79 | PDE4B (0.42) | PDE4BPDE4DPDE4ATYK2 | |
| SCHEMBL13929105 | 0.79 | PDE4B (0.50) | PDE4BPDE4DPDE4ATYK2CNR1 | |
| SCHEMBL8303245 | 0.79 | PDE4B (0.50) | PDE4BPDE4DPDE4ATYK2CNR1 | |
| SCHEMBL4182884 | 0.79 | PDE4B (0.50) | PDE4BPDE4DPDE4ATYK2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651640-B1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LTD (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | BARBER CHRISTOPHER G | 2006-08-10 | — | — | US | disclosed |
| US-20050043326-A1 | Compounds | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178408-A1 | Nicotinamide derivatives useful as pde4 inhibitors | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4D 5/4885PDE4A 1/4885 |
| US-20050043326-A1 | Compounds | NQO1, NAMPT, NNT | PDE4B 719/4885PDE4D 1102/4885PDE4A 1024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.